Ryan Haumschild, PharmD, MS, MBA, leads a discussion around the epidemiology of multiple sclerosis. Today, our panel of experts will explore the treatment landscape and impact of multiple sclerosis ...

DUBLIN--(BUSINESS WIRE)--The "Primary Progressive Multiple Sclerosis (PPMS) - An Overview" report has been added to Research and Markets' offering. The report provides an overview of primary ...

DUBLIN--(BUSINESS WIRE)--The "Secondary Progressive Multiple Sclerosis (SPMS) - Disease Overview" report has been added to Research and Markets' offering. Detailed overview of the SPMS disease area ...

Multiple sclerosis, or MS, is a central nervous system disorder that can cause progressively worse symptoms such as muscle weakness, blurred vision, and numbness. MS is typically diagnosed in a person ...

Multiple sclerosis (MS) is characterized by a broad array of symptoms. Despite this variability, most individuals with MS will exhibit a distinct set of symptoms during their initial clinical attack.

The Latest published Industry study on the “Multiple Sclerosis Therapeutics Market “ provides an overview of the current market dynamics in the Worldwide Multiple Sclerosis Therapeutics space, as well ...

DelveInsight's“ Multiple Sclerosis Pipeline Insight 2025 ” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Multiple Sclerosis pipeline landscape. It covers the ...

Multiple sclerosis can affect many areas of your daily life, including dental care. Symptoms of multiple sclerosis and the medications you take for these symptoms can lead to an increased need for ...

CHERRY HILL, N.J., Oct. 23, 2019 /PRNewswire/ -- The Multiple Sclerosis Association of America (MSAA), in partnership with Novartis Pharmaceuticals Corporation and Emmy Award-winning television ...

A multidisciplinary panel of experts provide an overview of the progressive nature of multiple sclerosis (MS) and discuss how clinicians, payers, and pharmacists approach management of the disease. To ...

The market for multiple sclerosis drugs is worth billions of dollars every year and these are the companies that benefit most. Multiple sclerosis, or MS, is a central nervous system disorder that can ...